


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in this application:

Listing of claims:

1. (Currently Amended) A ~~medicament containing at least one disorazole derivative of the general formula I~~

***Formula I***

in which independently of one another

R1 is:

- (i) hydrogen
- (ii) OR4
- (iii) part of a double bond to C5'

R2, R3 and R4 are:

- (i) hydrogen
- (ii) unsubstituted or substituted (C₁-C₆)-alkyl,
- (iii) (C₁-C₄)-alkyl substituted by one or more fluorine atoms, preferably a trifluoromethyl group,

- (iv) unsubstituted or substituted (C₁-C₄)-alkyl-(C₆-C₁₄)-aryl, unsubstituted or substituted (C₁-C₄)-alkyl-heteroaryl
- (v) (C₁-C₄)-alkoxycarbonyl, (C₁-C₄)-alkylaminocarbonyl (C₁-C₄)-alkylaminothiocarbonyl, (C₁-C₆)-alkyl-carbonyl or (C₁-C₆)-alkoxycarbonyl-(C₁-C₆)-alkyl,
it being possible for the substitution of the alkyl radical by F, Cl, Br, I, CN, NH₂, NH-(C₁-C₂₀)-alkyl, NH-(C₃-C₁₂)-cycloalkyl, OH, O-(C₁-C₂₀)-alkyl to take place singly or, on identical or different atoms, multiply by identical or different substituents, and it being possible for the substitution of an aryl radical by F, Cl, Br, I, CN, NH₂, NH-(C₁-C₂₀)-alkyl, OH, O-(C₁-C₂₀)-alkyl and/or (C₃-C₈)-heterocyclyl having 1 to 5 heteroatoms, preferably nitrogen, oxygen, sulfur to take place singly or, on identical or different atoms, multiply by identical or different substituents,

and

X, Y are: in each case individually independently of one another or together oxygen, sulfur, two vicinal hydroxyl groups, two vicinal methoxy groups, part of a double bond,


a compound being excluded in which R1 is methoxy, R2, R3 are hydrogen, X is oxygen and Y is the part of a double bond,

its tautomers, E/Z isomers, stereoisomers, including the diastereomers and enantiomers, and the physiologically tolerable salts thereof.

2. (Currently Amended) The medicament as claimed in claim 1, containing the disorazole derivative and pharmaceutically utilizable carriers and/or diluents and excipients in the form

~~of solutions, suspensions, emulsions, foams, ointments, pastes, patches or implants for administration. The compound of claim 1, wherein R1 and R2 are hydrogen, R3 is methyl and X and Y are oxygen.~~

3. (Currently Amended) The use of disorazole derivatives A pharmaceutical composition comprising a disorazole derivative of the general formula I



Formula 1

in which independently of one another

R1 is:

- (i) hydrogen
- (ii) OR4
- (iii) part of a double bond to C5'

R2, R3 and R4 are:

- (i) hydrogen
- (ii) unsubstituted or substituted (C₁-C₆)-alkyl,
- (iii) (C₁-C₄)-alkyl substituted by one or more fluorine atoms, preferably a trifluoromethyl group,

- (iv) unsubstituted or substituted (C_1 - C_4)-alkyl-(C_6 - C_{14})-aryl, unsubstituted or substituted (C_1 - C_4)-alkyl-heteroaryl,
- (v) (C_1 - C_4)-alkoxycarbonyl, (C_1 - C_4)-alkylaminocarbonyl (C_1 - C_4)-alkylaminothiocarbonyl, (C_1 - C_6)-alkyl-carbonyl or (C_1 - C_6)-alkoxycarbonyl-(C_1 - C_6)-alkyl,

it being possible for the substitution of the alkyl radical by F, Cl, Br, I, CN, NH₂, NH-(C_1 - C_{20})-alkyl, NH-(C_3 - C_{12})-cycloalkyl, OH, O-(C_1 - C_{20})-alkyl to take place singly or, on identical or different atoms, multiply by identical or different substituents, and it being possible for the substitution of an aryl radical by F, Cl, Br, I, CN, NH₂, NH-(C_1 - C_{20})-alkyl, OH, O-(C_1 - C_{20})-alkyl and/or (C_3 - C_8)-heterocyclyl having 1 to 5 heteroatoms, preferably nitrogen, oxygen, sulfur to take place singly or, on identical or different atoms, multiply by identical or different substituents,

and

X, Y are: in each case individually independently of one another or together oxygen, sulfur, two vicinal hydroxyl groups, two vicinal methoxy groups, part of a double bond,

a compound being excluded in which R1 is methoxy, R2, R3 are hydrogen, X is oxygen and Y is the part of a double bond,

~~its tautomers, E/Z isomers, stereoisomers, including the diastereomers and enantiomers, and the physiologically tolerable salts thereof, or its tautomer, E/Z isomer, stereoisomer, including diastereomer and enantiomer, or a physiologically tolerable salt thereof, and for the production of a medicament for the treatment of benign or malignant oncoses in humans or animals a pharmaceutically acceptable carrier, diluent or excipient.~~

4. (Currently Amended) ~~The use of disorazole derivatives of the general formula I as claimed in claim 3A method for the treatment of oncoses comprising administering the compound of claim 1 to an individual in need of such treatment alone or in combination with a cytotoxic substance and/or an inhibitor of signal transduction cytotoxic substances and/or inhibitors of signal transduction.~~
5. (Currently Amended) ~~The use of disorazole derivatives of the general formula I for the production of a medicament A method for the treatment of a disease in humans or animals which is based on the rapid and uncontrolled proliferation of endogenous cells comprising administering the compound of claim 1 to a human or animal in need of such treatment,~~
6. (Currently Amended) ~~The use of disorazole derivatives of the general formula I for the production of a medicament A method for the treatment of diseases which respond to immunomodulatory action comprising administering the compound of claim 1 to an individual in need of such treatment, such as psoriasis, arteriosclerosis, arthritis, keratoses, multiple sclerosis and cancer.~~
7. (Currently Amended) ~~The use of disorazole derivatives of the general formula I for the production of a medicament A method for the treatment of infective diseases comprising administering the compound of claim 1 to an individual in need of such treatment, such as cachexia, malaria, AIDS and infection related fever and pain.~~

8. (Currently Amended) The use of disorazole derivatives of the general formula I for the production of a medicament A method for the treatment of inflammatory and allergic diseases, inflammations mediated by eosinophils or proliferative diseases comprising administering the compound of claim 1 to an individual in need of such treatment such as airway diseases, bronchial asthma, allergic rhinitis, allergic conjunctivitis, eczema and Crohn's disease.
9. (Currently Amended) The use of the disorazole derivative E1 of the general formula I, in which R1 and R2 are hydrogen, R3 is methyl and X and Y are oxygen, as claimed in claim 3, for the production of a medicament A method for the treatment of benign or malignant oncoses in humans or animals comprising administering the compound of claim 1 to a human or animal in need of such treatment.
10. (Currently Amended) The methoduse of a disorazole derivative of the general formula I as claimed in claim 9 wherein the oncos is for the production of a medicament for the treatment of breast cancer, ovarian cancer, lung cancer, skin cancer, prostate cancer, renal cell cancer, hepatic cancer, pancreatic cancer, colonic cancer and cancers of the or brain cancer in humans.
11. (Currently Amended) The use of a disorazole derivative of the general formula I as claimed in claim 9 for the production of a medicament for the treatment of benign or malignant oncoses in humans or animals The method of claim 9, wherein the compound of claim 1 is administered in combination with another antitumor agent other antitumor agents.

12. (Currently Amended) ~~The use of a disorazole derivative of the general formula I as claimed in claim 9 for the production of a medicament for the treatment of benign or malignant neoposes in humans or animals~~ The method of claim 9, wherein the compound of claim 1 is administered in combination with paclitaxel, docetaxel, vincristine, vindesine, cisplatin, carboplatin, doxorubicin, ifosfamide, cyclophosphamide, 5-FU, methotrexate or in combination with an immunomodulator or antibody or immunomodulators or antibodies and in particular in combination with inhibitors of a signal transduction inhibitor such as Herceptin, Glivec or Iressa.

13. (Currently Amended) ~~The use of a disorazole derivative of the general formula I as claimed in claim 10 for the production of a medicament for the treatment of benign or malignant neoposes in humans or animals in combination with other antitumor agents~~ The method of claim 12, wherein the signal transduction inhibitor is Herceptin, Glivec or Iressa.

14. (Currently Amended) ~~The use of a disorazole derivative of the general formula I as claimed in claim 10 for the production of a medicament for the treatment of benign or malignant neoposes in humans or animals in combination with paclitaxel, docetaxel, vincristine, vindesine, cisplatin, carboplatin, doxorubicin, ifosfamide, cyclophosphamide, 5-FU, methotrexate or in combination with immunomodulators or antibodies and in particular in combination with inhibitors of signal transduction such as Herceptin, Glivec or Iressa and others~~ The pharmaceutical composition of claim 3, which is in the form of a solution, suspension, emulsion, foam, ointment, paste, patch or implant.

15. (Currently Amended) ~~The use of a diserazole derivative of the general formula I as claimed in claim 11 for the production of a medicament for the treatment of benign or malignant neoposes in humans or animals in combination with paclitaxel, docetaxel, vincristine, vindesine, cisplatin, carboplatin, doxorubicin, ifosfamide, cyclophosphamide, 5-FU, methotrexate or in combination with immunomodulators or antibodies and in particular in combination with inhibitors of signal transduction such as Herceptin, Clivex or Iressa and others~~ The method of claim 6, wherein the disease is psoriasis, arteriosclerosis, arthritis, keratosis, multiple sclerosis or cancer.

16. (New) The method of claim 7, wherein the disease is cachexia, malaria, AIDS or infection-related fever and pain.

17. (New) The method of claim 8, wherein the disease is an airway disease, bronchial asthma, allergic rhinitis, allergic conjunctivitis, eczema or Crohn's disease.